[A prospective and randomized study of the complete response, index of recurrences and progression in superficial bladder carcinoma treated with mitomycin C alone versus mitomycin C and BCG alternatively].
The results of a comparative randomized study on intravesical chemoprophylaxis are presented. The study comprised 66 patients; one group of 29 patients received mitomycin C alone, while another group of 37 patients received mitomycin C and alternating BCG therapy. This latter treatment modality was found to achieve a slightly higher complete response rate and a much lower tumor progression rate. Although these results were not statistically significant (p > 0.05), they indicate that if the study were comprised of a larger series, the combined modality may be shown to achieve better results than the other modalities currently used.
Gelabert-Mas
A
A
Servicio de Urología, Hospital del Mar, Universidad Autónoma de Barcelona, España.
Arango Toro
O
O
Bielsa Gali
O
O
Lladó Carbonell
C
C
D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D016009:Chi-Square Distribution; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000009:adverse effects / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D011446:Prospective Studies; D012074:Remission Induction; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control
D001500:BCG Vaccine; D016685:Mitomycin
Estudio prospectivo y randomizado de la respuesta completa, índice de recidivas y progresión en el carcinoma vesical superficial tratado con mitomycina-C sola versus mitomycina-C y BCG alternos.